Aurinia Pharmaceuticals Inc. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated November 14, 2017, is a report of a foreign private issuer filed by Aurinia Pharmaceuticals Inc. The filing incorporates by reference the Interim Condensed Consolidated Financial Statements and Management's Discussion and Analysis (MD&A) for the third quarter ended September 30, 2017.
Key Financial Metrics
The provided text serves as a cover sheet and exhibit index. It does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the incorporated exhibits (99.1 and 99.2) which are not included in the input text.
Material Changes
The filing text does not provide details on material changes versus the prior comparable period. Such analysis is contained within the MD&A (Exhibit 99.2) referenced in this report.
Guidance, Outlook, and Risks
No guidance, outlook, management commentary, risks, contingencies, or unusual items are detailed in the provided text. This information is expected to be found in the incorporated MD&A (Exhibit 99.2).
Investor Verification Checklist
- Verify the specific financial results for the quarter ended September 30, 2017, by reviewing Exhibit 99.1 (Interim Condensed Consolidated Financial Statements).
- Review Exhibit 99.2 (MD&A) for management's discussion of liquidity, capital resources, and operational updates.
- Confirm the status of the Registration Statement on Form F-10 (File No. 333-206994) to which this report is incorporated.
- Check the certifications signed by the Chief Executive Officer and Chief Financial Officer (Exhibits 99.3 and 99.4) for any disclosures regarding internal controls.